Teva presents positive efficacy and safety data of ajovy® (fremanezumab) for the prevention of episodic migraine in children and adolescents from phase 3 space trial

Tel aviv, israel, dec. 04, 2024 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) presented positive data from its phase 3 space study evaluating the efficacy and safety of ajovy® (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.1 the trial showed statistically significant superior efficacy compared to placebo over 12 weeks with a favourable safety profile1 consistent with that observed in the adult population.
TEVA Ratings Summary
TEVA Quant Ranking